Sol-Gel Technologies

SLGL

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Good

Valuation

Data not available

Track this stock — start free trial

Winston Score History

The full picture

Sol-Gel Technologies is an Israeli pharmaceutical company that develops and sells prescription skin treatments. Its main product is TWYNEO, a cream used to treat acne, and it also sells EPSOLAY, a cream for a skin condition called rosacea. The company focuses on dermatology — the branch of medicine dealing with skin — and sells its products primarily to patients in the United States through partnerships with larger pharmaceutical distributors.

Sol-Gel makes money by selling its prescription creams, earning revenue each time a pharmacy fills a patient's prescription. The company is based in Israel but generates most of its commercial revenue in the U.S. market. Its 100% gross margin reflects the high value of branded prescription drugs relative to their manufacturing cost, though the company is still spending heavily on sales and operations, resulting in overall losses. The key growth driver is expanding the number of doctors who prescribe its products, while the main risk is competition from cheaper generic acne and rosacea treatments already on the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-96.6% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-127.1% YoY

YoY Growth Rate

Earnings declining

Insider Activity

73.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$49M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Sol-Gel Technologies's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

0.0%

Thin — 0.0% gross margin

Profit after running costs

Operating Margin

-704.2%

Losing money on operations — -704.2%

Return on the money invested

ROCE

-36.4%

Weak — -36.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-92.5%

Shrinking sales (-92.5% YoY)

Profit growth

EPS YoY

-255.5%

Earnings shrinking (-255.5% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

How steady the profit is

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

0.0%

Thin free cash flow (0.0%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.01

Conservative — low debt load (0.01)

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial